GC Biopharma Corp. (006280.KS)
| Previous Close | 115,700.00 |
| Open | 114,700.00 |
| Bid | 117,400.00 x 0 |
| Ask | 117,500.00 x 0 |
| Day's Range | 114,600.00 - 117,900.00 |
| 52 Week Range | 93,000.00 - 131,100.00 |
| Volume | |
| Avg. Volume | 19,762 |
| Market Cap | 1.341T |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 1,500.00 (1.30%) |
| Ex-Dividend Date | Dec 27, 2023 |
| 1y Target Est | 144,333.00 |
PR NewswireGC Cell participates 2024 BIO International Convention, Unveiling its future Blueprint 2.0, as the First Korean Business Forum Sponsor
GC Cell, a leader in the cell and gene therapy (CGT) sector within the biopharmaceutical industry, proudly announces its role as the first Korean Business Forum sponsor at the upcoming 2024 BIO International Convention. Set to take place in San Diego from June 3-6, this year's convention is themed "Making the Impossible Possible" and anticipates participation from over 1,500 companies and 20,000 attendees worldwide.
PR NewswireGC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A.
- PR Newswire
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval.
